Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification

por Disel, Umut, Germain, Alexis, Yilmazel, Bahar, Abali, Huseyin, Bolat, Filiz Aka, Yelensky, Roman, Elvin, Julia A., Lipson, Doron, Chmielecki, Juliann, Wang, Kai, Stephens, Philip J., Ross, Jeffrey S., Miller, Vincent A., Ali, Siraj M., George, Thomas J.
Publicado 2015